DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 018057/SLR-083

SUPPLEMENT APPROVAL

HQ Specialty Pharma
Attention: Jeanne Squeglia
120 Route 17 North
Paramus, NJ 07652

Dear Ms. Squeglia:

Please refer to your Supplemental New Drug Application (sNDA) dated December 10, 2013, received December 10, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for CISplatin Injection, sterile aqueous injection 1 mg/mL (50 mg/50 mL and 100 mg/100 mL).

This Prior Approval supplemental new drug application is in response to the November 4, 2013, Prior Approval supplement request letter requesting the following label changes:

- Remove the entire CLINICAL PHARMACOLOGY, Pharmacogenomics subsection
- From the WARNINGS section, remove the following statement: "Certain genetic variants in the thiopurine S-methyltransferase (TPMT) gene are associated with increased risk of ototoxicity in children administered conventional doses of cisplatin (see CLINICAL PHARMACOLOGY). Children who do not have one of these TPMT gene variants remain at risk for ototoxicity."
- From the PRECAUTIONS, Pediatric Use subsection, remove the following statement: "Variants in the thiopurine S-methyltransferase (TPMT) gene are associated with an increased risk of ototoxicity in children treated with cisplatin (see CLINICAL PHARMACOLOGY)."
- In the ADVERSE REACTIONS, Ototoxicity subsection, remove the following statement regarding genetic factors that may contribute to ototoxicity in children: "Variants in the thiopurine S-methyltransferase gene (TPMT) have been reported to be associated with an increased risk of ototoxicity in children treated with cisplatin." Modify the statement "Other genetic factors may also contribute to the cisplatin-induced ototoxicity" so that this reads "Genetic factors (e.g. variants in the thiopurine S-methyltransferase [TPMT] gene) may contribute to cisplatin-induced ototoxicity; although this association has not been consistent across populations and study designs." Remove the cross reference to the CLINICAL PHARMACOLOGY section (i.e., "see CLINICAL PHARMACOLOGY)" related to these statements.

In addition, this supplement provides for the following revisions:

1. Delete the tradename Platinol®
2. Propose the drug name CISplatin

Please note that when the Proprietary name is removed from approved labeling it must also be removed from the Orange Book.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the

revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amy Tilley, Regulatory Project Manager, at 301-796-3994.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Acting Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
02/26/2015